Entellus Medical, Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 3,972 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $19.10, for a total transaction of $75,865.20. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Brian E. Farley also recently made the following trade(s):

  • On Tuesday, October 3rd, Brian E. Farley sold 6,028 shares of Entellus Medical stock. The stock was sold at an average price of $19.17, for a total transaction of $115,556.76.

Shares of Entellus Medical, Inc. (NASDAQ:ENTL) opened at 20.30 on Friday. The company has a 50-day moving average of $18.04 and a 200 day moving average of $18.04. The firm’s market capitalization is $515.03 million. Entellus Medical, Inc. has a 12-month low of $12.31 and a 12-month high of $21.93.

Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The business had revenue of $22.10 million during the quarter, compared to the consensus estimate of $21.87 million. During the same period in the prior year, the company posted ($0.27) earnings per share. The firm’s revenue was up 18.0% compared to the same quarter last year. On average, analysts predict that Entellus Medical, Inc. will post ($1.61) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.watchlistnews.com/entellus-medical-inc-entl-director-sells-75865-20-in-stock/1614978.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC bought a new stake in shares of Entellus Medical in the first quarter valued at approximately $290,000. Nicholas Company Inc. boosted its position in shares of Entellus Medical by 1,052.3% in the second quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock valued at $4,101,000 after acquiring an additional 226,190 shares during the period. Swiss National Bank boosted its position in shares of Entellus Medical by 98.9% in the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock valued at $244,000 after acquiring an additional 8,800 shares during the period. William Blair Investment Management LLC boosted its position in shares of Entellus Medical by 10.5% in the second quarter. William Blair Investment Management LLC now owns 431,187 shares of the medical technology company’s stock valued at $7,140,000 after acquiring an additional 40,853 shares during the period. Finally, Archon Capital Management LLC boosted its position in shares of Entellus Medical by 34.3% in the second quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock valued at $7,929,000 after acquiring an additional 122,171 shares during the period. 70.24% of the stock is owned by institutional investors.

ENTL has been the topic of a number of recent research reports. Piper Jaffray Companies reissued a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Zacks Investment Research cut shares of Entellus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, BidaskClub cut shares of Entellus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 8th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Entellus Medical presently has an average rating of “Hold” and an average price target of $21.83.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.